Fundraising FoxExpansion Therapeutics
Del Mar, US · Founded 2016 · Delaware corporation · 6 known investors
Find your way into Expansion Therapeutics
Sign up to see every warm intro you have to Expansion Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Expansion Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Drug discovery company focused on RNA-targeted small molecule therapeutics for expansion repeat disorders.
Founders & leadership
Expansion Therapeutics was founded in 2016 by Matthew Disney.
Board
Investors · 6
How we know: 5AM Ventures's portfolio page · a partner's Signal profile · funding news · press coverage · Not right? Tell us
How we know: Sanofi Ventures's portfolio page · board seat on SEC Form D · funding news · press coverage · Not right? Tell us
How we know: funding news · press coverage · Not right? Tell us
How we know: funding news · press coverage · Not right? Tell us
How we know: press coverage · Not right? Tell us
How we know: press coverage · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$78.3M disclosed across 3 rounds · 2016–2021
▶$48MraisedOct 2021 · 12 investors · PharmaceuticalsRule 506(b)
- Renato Skerlj, Ph.D.Executive Officer, Director
- Laura Tadvalkar, Ph.D.Director
- Andy Phillips, Ph.D.Director
- Scott Rocklage, Ph.D.Director
- Beth Seidenberg, M.D.Director
- Offering amount
- $80.1M
- Amount sold
- $48M
- First sale
- Sep 2021
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$25.3MraisedJan 2018 · 8 investors · PharmaceuticalsRule 506(b)
- Kevin Forrest, Ph.D.Executive Officer, Director
- Campbell Murray, M.B.B.S., M.B.A.Director
- Yujiro Hata, M.B.A.Director
- Matthew Disney, Ph.D.Director
- Beth Seidenberg, M.D.Director
- Scott Rocklage, Ph.D.Director
- Jason Hafler, Ph.D.Director
- Offering amount
- $55.3M
- Amount sold
- $25.3M
- First sale
- Dec 2017
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$5MraisedJun 2017 · 3 investors · PharmaceuticalsRule 506(b)
- Paul StoneExecutive Officer
- Yujiro HataDirector
- Kevin ForrestExecutive Officer, Director
- Scott RocklageExecutive Officer, Director
- Matthew DisneyDirector
- Jason HaflerDirector
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- Nov 2016
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Expansion Therapeutics do?
- Drug discovery company focused on RNA-targeted small molecule therapeutics for expansion repeat disorders.
- Who founded Expansion Therapeutics?
- Expansion Therapeutics was founded by Matthew Disney in 2016.
- Who are Expansion Therapeutics's investors?
- Expansion Therapeutics's investors include 5AM Ventures, Sanofi Ventures, Kleiner Perkins, Novartis Venture Fund, RA Capital, Westlake Village BioPartners.
- How much funding has Expansion Therapeutics raised?
- Expansion Therapeutics has disclosed $78.3M raised across 3 rounds.
- Where is Expansion Therapeutics headquartered?
- Expansion Therapeutics is headquartered in Del Mar, US.